Formycon is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $31.7B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Formycon's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Keytruda FYB206 |
Merck | Biosimilar | 2028 | Filed with the FDA 2026. FDA accepted the application for review in Oct 2026; decision expected Q3 2027 | $31.7B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Formycon's share of it.
Formycon has applications filed for Keytruda. Of the 70 makers we follow, 38 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.